A Phase 1b/2 Study of the Safety and Efficacy of the Monoclonal Antibody OM-RCA-01 in Patients With Metastatic Tumors Expressing Fibroblast Growth Factor Receptor 1

Recruiting

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(5 sites)

Russia

Republican Dispensary of Tatarstan, Kazan'

A.I. Kryzhanovsky Krasnoyarsk Regional Cancer Center, Krasnoyarsk

Hadassah Medical, Moscow

I.P. Pavlov First Saint Petersburg State Medical University, Saint Petersburg

Republican Clinical Oncology Dispensary, Ufa